Pharvaris B.V. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Pharvaris B.V. | PHVS - NASDAQ |
$17.00-$19.00 | $20.00 | $25.00 | 8.3 million | 2/5/2021 |
| Morgan Stanley, BofA Securities, SVB Leerink | ||||||
Co-Manager(s): Oppenheimer, Kempen & Co.
| ||||||
| Health Care | ||||||
Filing(s): Filed 2021-01-15 Terms Added 2021-02-01 | ||||||
Pharvaris B.V. Quote & Chart - Click for current quote - PHVS
IPO Boutique aggregates information on public companies and private companies, such as "PHVS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Pharvaris B.V. (adapted from Pharvaris B.V. prospectus):
They are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PHVS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.